0.8(top 50%)
impact factor
962(top 20%)
papers
13.0K(top 20%)
citations
49(top 10%)
h-index
0.8(top 50%)
impact factor
997
all documents
13.4K
doc citations
77(top 10%)
g-index

Top Articles

#TitleJournalYearCitations
1ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous DisordersSarcoidosis Vasculitis and Diffuse Lung Diseases1999736
2The WASOG Sarcoidosis Organ Assessment Instrument: An update of a previous clinical toolSarcoidosis Vasculitis and Diffuse Lung Diseases2014273
3Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A Case Control Etiologic Study of SarcoidosisSarcoidosis Vasculitis and Diffuse Lung Diseases1999231
4Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trialSarcoidosis Vasculitis and Diffuse Lung Diseases2000201
5The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United StatesSarcoidosis Vasculitis and Diffuse Lung Diseases2012168
6Infliximab for refractory sarcoidosisSarcoidosis Vasculitis and Diffuse Lung Diseases2001164
7The major histopathologic pattern of pulmonary fibrosis in scleroderma is nonspecific interstitial pneumoniaSarcoidosis Vasculitis and Diffuse Lung Diseases2002131
8Risk factors of acute exacerbation of idiopathic pulmonary fibrosisSarcoidosis Vasculitis and Diffuse Lung Diseases2010129
9Two year prognosis of sarcoidosis: the ACCESS experienceSarcoidosis Vasculitis and Diffuse Lung Diseases2003122
10A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosisSarcoidosis Vasculitis and Diffuse Lung Diseases2006118
11Efficacy of corticosteroids in sarcoidosis presenting with atrioventricular blockSarcoidosis Vasculitis and Diffuse Lung Diseases200397
12Pulmonary alveolar microlithiasis: report on 576 cases published in the literatureSarcoidosis Vasculitis and Diffuse Lung Diseases200494
13Cells and cytokines involved in the pathogenesis of sarcoidosisSarcoidosis Vasculitis and Diffuse Lung Diseases199990
14Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG Task ForceSarcoidosis Vasculitis and Diffuse Lung Diseases201190
15Sarcoidosis in Denmark 1980-1994. A registry-based incidence study comprising 5536 patientsSarcoidosis Vasculitis and Diffuse Lung Diseases200385
16Report on the incidence of interstitial lung diseases in SpainSarcoidosis Vasculitis and Diffuse Lung Diseases200478
17Pulmonary hypertension in sarcoidosisSarcoidosis Vasculitis and Diffuse Lung Diseases200678
18Inhaled iloprost for sarcoidosis associated pulmonary hypertensionSarcoidosis Vasculitis and Diffuse Lung Diseases200978
19Propionibacterium acnes is the most common bacterium commensal in peripheral lung tissue and mediastinal lymph nodes from subjects without sarcoidosisSarcoidosis Vasculitis and Diffuse Lung Diseases200575
20A prospective study of 32 patients with neurosarcoidosisSarcoidosis Vasculitis and Diffuse Lung Diseases200373
21Practical eminence and experience-based recommendations for use of TNF-α inhibitors in sarcoidosisSarcoidosis Vasculitis and Diffuse Lung Diseases201469
22Calcium and vitamin D metabolism in sarcoidosisSarcoidosis Vasculitis and Diffuse Lung Diseases201368
23Predicting respiratory failure in sarcoidosis patientsSarcoidosis Vasculitis and Diffuse Lung Diseases199767
24Sleep apnea in sarcoidosisSarcoidosis Vasculitis and Diffuse Lung Diseases199765
25Exaggerated TNFalpha release of alveolar macrophages in corticosteroid resistant sarcoidosisSarcoidosis Vasculitis and Diffuse Lung Diseases200264
26Surfactant protein D and KL-6 serum levels in systemic sclerosis: correlation with lung and systemic involvementSarcoidosis Vasculitis and Diffuse Lung Diseases201164
27Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosisSarcoidosis Vasculitis and Diffuse Lung Diseases200963
28Surgical lung biopsy for the diagnosis of interstitial lung disease: a review of the literature and recommendations for optimizing safety and efficacySarcoidosis Vasculitis and Diffuse Lung Diseases201362
29Drug-induced pneumonitis: the role of methotrexateSarcoidosis Vasculitis and Diffuse Lung Diseases200161
30Sarcoidosis: genes and microbes--soil or seed?Sarcoidosis Vasculitis and Diffuse Lung Diseases200160
31Ambrisentan for sarcoidosis associated pulmonary hypertensionSarcoidosis Vasculitis and Diffuse Lung Diseases201160
32Course of asymptomatic liver involvement in sarcoidosis: role of therapy in selected casesSarcoidosis Vasculitis and Diffuse Lung Diseases199757
33Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use themSarcoidosis Vasculitis and Diffuse Lung Diseases200856
34Surfactant protein-D predicts survival in patients with idiopathic pulmonary fibrosisSarcoidosis Vasculitis and Diffuse Lung Diseases200956
35Efficacy Results of a 52-week Trial of Adalimumab in the Treatment of Refractory SarcoidosisSarcoidosis Vasculitis and Diffuse Lung Diseases201455
36Proliferative response of peripheral blood mononuclear cells and levels of antibody to recombinant protein from Propionibacterium acnes DNA expression library in Japanese patients with sarcoidosisSarcoidosis Vasculitis and Diffuse Lung Diseases200055
37Use of fluticasone in acute symptomatic pulmonary sarcoidosisSarcoidosis Vasculitis and Diffuse Lung Diseases200254
38Epithelial stem cell exhaustion in the pathogenesis of idiopathic pulmonary fibrosisSarcoidosis Vasculitis and Diffuse Lung Diseases201053
39Endpoints for clinical trials of sarcoidosisSarcoidosis Vasculitis and Diffuse Lung Diseases201253
40Clinical course and outcome of rheumatoid arthritis-related usual interstitial pneumoniaSarcoidosis Vasculitis and Diffuse Lung Diseases201353
41Clinical experience with pirfenidone in five patients with scleroderma-related interstitial lung diseaseSarcoidosis Vasculitis and Diffuse Lung Diseases201453
42Treatment and outcome of lung cancer in idiopathic interstitial pneumoniasSarcoidosis Vasculitis and Diffuse Lung Diseases201553
43Pulmonary hypertension in idiopathic pulmonary fibrosis: a reviewSarcoidosis Vasculitis and Diffuse Lung Diseases200952
44Overexpression of transforming growth factor-alpha and epidermal growth factor-receptor in idiopathic pulmonary fibrosisSarcoidosis Vasculitis and Diffuse Lung Diseases199951
45Management of ocular sarcoidosisSarcoidosis Vasculitis and Diffuse Lung Diseases201251
46Th1 and Th2 responses regulate experimental lung granuloma developmentSarcoidosis Vasculitis and Diffuse Lung Diseases199650
47Efficacy of azathioprine as second-line treatment in pulmonary sarcoidosisSarcoidosis Vasculitis and Diffuse Lung Diseases199950
48Sarcoidosis on tattoos: a review of the literature from 1939 to 2011Sarcoidosis Vasculitis and Diffuse Lung Diseases201350
49Relationship between outcome measures of six-minute walk test and baseline lung function in patients with interstitial lung diseaseSarcoidosis Vasculitis and Diffuse Lung Diseases200149
50CSF-ACE activity in probable CNS neurosarcoidosisSarcoidosis Vasculitis and Diffuse Lung Diseases200249